Annovis Bio (ANVS)
(Delayed Data from NYSE)
$9.14 USD
+1.16 (14.54%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.10 -0.04 (-0.44%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.14 USD
+1.16 (14.54%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $9.10 -0.04 (-0.44%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Zacks News
New Strong Buy Stocks for April 18th
by Zacks Equity Research
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep going
by Zacks Equity Research
Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
by Zacks Equity Research
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
by Zacks Equity Research
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
by Zacks Equity Research
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
by Zacks Equity Research
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
by Zacks Equity Research
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
by Zacks Equity Research
Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
by Zacks Equity Research
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 152.89%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 152.9% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging McKesson (MCK) This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 251.4% in Annovis Bio, Inc. (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Annovis (ANVS) Gains on FDA Authorization for AD Study
by Zacks Equity Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
by Zacks Equity Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD
by Zacks Equity Research
Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.